Metabolism Disorder TRIZ Cases

A rice protein isolate supplement enhances muscle mass and strength through a specific amino acid profile.

Agonistic anti-CD137 antibodies with modified Fc regions enhance T cell activity and reduce tumor growth in animal models.

Selective cannabimimetic imidazole ligands reduce side effects by targeting CB1 and CB2 receptors for fibrosis treatment.

Recombinant microorganisms produce nutritive proteins with optimized amino acid ratios to reduce dietary protein requirements and environmental impact.

A disconnectable insulin delivery system calculates a pre-disconnection bolus dose based on current glucose levels and sensitivity.

Portal vein administration of purified adipose progenitor cells achieves high hepatocyte engraftment, resolving donor shortages and reducing patient burden.

Combines amodiaquine with antidiabetic drugs to activate PPAR-alpha and gamma receptors simultaneously.

Segmented dual-agonist molecules combine GLP-1 and GIP segments to resolve activation level trade-offs, enhancing weight loss while reducing nausea.

Staphylococcal enterotoxins activate T-cells to reverse insulin resistance and stabilize postprandial glucose in type 2 diabetes.

Optimized pH and sialic acid levels stabilize high-concentration human tissue kallikrein-1, preventing aggregation while enabling subcutaneous delivery.

Polyhydroxy additives enhance peptide solubility within lipid matrices, enabling stable release profiles without initial burst concentrations.

Preformed cyclodextrin inclusion complexes replace guest molecules with fatty acids in the gut, reducing fat absorption without complex manufacturing steps.

Metformin pharmaceutical compositions utilize peroxide impurities to oxidize nitrosable compounds into non-nitrosable forms during granulation.

Determining oxidized apolipoprotein A-I levels in biological samples to identify cardiovascular disease risk.

Cyclic peptides scavenge methylglyoxal via lysine and Dap residues, extending plasma half-life beyond small molecule limits.

A nutritional composition using oligosaccharides and cysteine addresses immune dysfunction, intestinal issues, and low glutathione status in HIV patients.

Ester prodrugs with dipeptide extensions modify GLP-1 peptides to enable slow biotransformation, resolving short plasma half-life and DPP-IV degradation.

Sphingolipid-like compounds mitigate leptin resistance by inhibiting ARF6 to restore mitochondrial fusion.

Diboron compounds bind albumin to create glucose-sensitive insulin derivatives that displace insulin during hyperglycemia, preventing hypoglycemia.

CasX:gNA system modifies PCSK9 genes via virus-like particles, reducing off-target effects and genome instability.

Conjugating biotin to specific lysine residues on exendin-4 derivatives resists DPP-IV degradation, extending therapeutic duration without side effects.

Sequential growth factor stages differentiate pluripotent stem cells into precise pancreatic endocrine populations, resolving efficiency and purity trade-offs.

Terpene-free coating layers on a medicament-containing layer effectively mask unpleasant taste from drugs like loxoprofen, resolving patient rejection issues.

Elapidae Phospholipase A2 monomers reduce urinary microalbumin and beta-2 microglobulin levels to restore renal function.

Balanced DHA, EPA, and ARA ratios in lipid emulsions reduce liver injury markers while enhancing fatty acid deposition in developing tissues.

Truncated crosslinked polypeptides resist proteolytic degradation to extend half-life, enabling oral administration for type 2 diabetes treatment.

Hydrolyzing soybean residues with proteases yields bioactive peptides promoting cholecystokinin secretion, eliminating complex purification steps.

Staged pluripotent stem cell differentiation produces transplantable pancreatic endocrine precursor cells to lower blood glucose levels in diabetic models.

Conjugating oxyntomodulin to an immunoglobulin Fc region extends half-life while replacing albumin with sugar alcohols to eliminate viral contamination risks.

Modifications at positions 14, 17, and 26 enhance peptide stability and reduce gastrointestinal side effects while maintaining therapeutic efficacy.

Lactobacillus rhamnosus strains establish early bifidogenic gut microflora in infants to lower body mass index at age four.

Targeting the NKp46 D1 domain with hNKp46.02 induces receptor internalization, bypassing complex ligand recognition mechanisms.

Directly linked di-ubiquitin muteins resolve the contradiction between binding affinity and low expression rates, enabling effective targeting of Her2 and EGFR.

CYP4A inhibitor composition reduces blood insulin levels and hepatocyte apoptosis to treat diabetes and fatty liver.

Soluble GHS-R1a fusion protein binds ghrelin, preventing receptor activation and reducing weight gain without affecting food intake.

Guanidinoacetic acid resists gastric breakdown and processing degradation, converting to creatine only after absorption to ensure high bioavailability.

Multi-ingredient homeopathic drug formulation targets metabolic activation and appetite suppression.

High-dose ethyl icosapentate suppresses cardiovascular events in primary prevention patients with multiple risk factors where statins fail.

A combination therapy using an opioid antagonist and alpha-MSH agonist to reduce food cravings.

A gastrin-17 peptide immunogenic composition linked to a peptidic alpha-helix enhances immune response specificity through coiled coil interactions.

Targeting IgE signaling with monoclonal antibodies addresses unmet needs in cardiovascular care by reducing lesion formation and improving metabolic conditions.

Self-complementary AAV vectors deliver the LIPA gene to hepatocytes, correcting enzymatic deficiency and reducing lipid accumulation in Wolman disease.

Targeted manganese superoxide dismutase reduces intestinal superoxide levels, resolving oxidative stress without impairing hepatic mitochondrial function.

Zinc lactate gluconate and copper ion source dissolve in water to create a stable hydration supplement that prevents precipitation during cold-filling.

IGF-2 treatment restores beta cell function to maintain stable blood glucose, reducing reliance on daily exogenous insulin injections.

Modified glucagon analogues substitute amino acid residues at positions 3 and 4 to enhance receptor binding potency and selectivity.

Lipid compound and gum emulsion encapsulates active ingredients, improving storage stability and controlled release.

Linking albumin binding residues to growth hormone variants extends half-life and reduces administration frequency.

Lipophilic exendin-4 modifications enhance receptor activation, reversing fibrosis where current drugs fail.

A semi-recombinant method couples recombinant C-terminal precursors with chemical N-terminal extensions containing non-proteogenic amino acids.